Peripherin is a biomarker of axonal damage in peripheral nervous system disease

Abstract

Valid, responsive blood biomarkers specific to peripheral nerve damage would improve management of peripheral nervous system (PNS) diseases. Neurofilament light chain (NfL) is sensitive for detecting axonal pathology but is not specific to PNS damage, as it is expressed throughout the PNS and central nervous system (CNS). Peripherin, another intermediate filament protein, is almost exclusively expressed in peripheral nerve axons. We postulated that peripherin would be a promising blood biomarker of PNS axonal damage. We demonstrated that peripherin is distributed in sciatic nerve, and to a lesser extent spinal cord tissue lysates, but not in brain or extra-neural tissues. In the spinal cord, anti-peripherin antibody bound only to the primary cells of the periphery (anterior horn cells, motor axons and primary afferent sensory axons). In vitro models of antibody-mediated axonal and demyelinating nerve injury showed marked elevation of peripherin levels only in axonal damage and only a minimal rise in demyelination. We developed an immunoassay using single molecule array (Simoa) technology for the detection of serum peripherin as a biomarker for PNS axonal damage. We examined longitudinal serum peripherin and NfL concentrations in individuals with Guillain-Barré syndrome (GBS, n = 45, 179 timepoints), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP, n = 35, 70 timepoints), multiple sclerosis (MS, n = 30), dementia (as non-inflammatory CNS controls, n = 30) and healthy individuals (n = 24). Peak peripherin levels were higher in GBS than all other groups (median 18.75 pg/mL vs. < 6.98 pg/mL, p < 0.0001). Peak NfL was highest in GBS (median 220.8 pg/mL) and lowest in healthy controls (median 5.6 pg/mL), but NfL did not distinguish between CIDP (17.3 pg/mL), MS (21.5 pg/mL) and dementia (29.9 pg/mL). While peak NfL levels were higher with older age (rho=+0.39, p < 0.0001), peak peripherin levels did not vary with age. In GBS, local regression analysis of serial peripherin in the majority of individuals with 3 or more timepoints of data (16/25) displayed a rise-and-fall pattern with the highest value within the first week of initial assessment. Similar analysis of serial NfL concentrations showed a later peak at 16 days. Group analysis of serum peripherin and NfL levels in GBS and CIDP patients were not significantly associated with clinical data, but in some individuals with GBS, peripherin levels appeared to better reflect clinical outcome measure improvement. Serum peripherin is a promising new, dynamic, and specific biomarker of acute PNS axonal damage.

Mitigating Critical Peripheral Nerve Deficit Therapy with Reactive Oxygen Species/Ca2+-Responsive Dynamic Hydrogel-Mediated mRNA Delivery

“…Injuries to the nervous system frequently result in limb dysfunction and, in severe cases, even paralysis. When juxtaposed with the central nervous system, peripheral nerves exhibit a heightened regenerative capacity capable of spontaneous recovery postinjury . The effectiveness of nerve repair is primarily contingent upon the interplay between regenerative potential and the nurturing microenvironment .…”

Nerve conduction features may serve as a diagnostic clue for neuronal intranuclear inclusion disease

“…Further pathological investigations, such as nerve biopsy and immunohistological analysis, could provide insights into the pre-clinical pathological change of NIID neuropathy. In addition, recent advancements in diagnostic fluid biomarkers 25 from peripheral nerve damage offer an opportunity to identify small molecule biomarkers associated with ubiquitous neuropathy among NIID patients.…”

Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathy

“…Even if measured with a very sensitive assay, sNfL levels are not suited to objectify or to monitor loss of small epidermal nerve fibers in SFN. Future research has to clarify whether the amount of NfL in epidermal nerve fibers is too low, whether other filament proteins like the recently investigated peripherin [72] are better suited to monitor small nerve fiber damage, or whether the pathophysiology of SFN is not related to an ongoing axonal damage.…”